James Larkin
Team Leader
Melanoma and Kidney Cancer
The Institute Of Cancer Research
United Kingdom
Biography
Dr James Larkin is a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust specialising in the treatment of melanoma and cancers of the kidney. Dr Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at The Institute of Cancer Research, London, which led to the award of a PhD. He completed specialist training at The Royal Marsden and was appointed a Consultant in 2008.
Research Interest
His research interests involve trying to understand cancer and its consequences better, as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He has served as UK and Global Chief Investigator for a number of clinical trials in melanoma and kidney cancer, many leading to the approval of new drugs for the treatment of advanced disease. He has been awarded research grants from bodies including Cancer Research UK, the Wellcome Trust and the European Framework Programme 7.
Publications
-
Bracarda, S., Negrier, S., Casper, J., Porta, C., Schmidinger, M., Larkin, J., Gross Goupil, M. & Escudier, B. (2017). How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert review of anticancer therapy, Vol.17(3), pp. 227-233.
-
Spain, L., Schmid, T., Gore, M. & Larkin, J. (2017). Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. European journal of cancer, Vol.75, pp. 243-244.
-
Arce Vargas, F., Furness, A.J., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M.H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, Vol.46(4), pp. 577-586.
-
Weber, J.S., Hodi, F.S., Wolchok, J.D., Topalian, S.L., Schadendorf, D., Larkin, J., Sznol, M., Long, G.V., Li, H., Waxman, I.M., et al. (2017). Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology, Vol.35(7), pp. 785-792.
-
Reynolds, A., bridgeman, V., vermeulen, P., foo, S., bilezc, A., daley, F., kostaras, E., nathan, M., wan, E., frentzas, S., et al. (2017). Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. Journal of pathology, Vol.241(3), pp. 362-374.
-
Spain, L., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J. & Larkin, J., et al. (2017). Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Annals of oncology, Vol.28(2), pp. mdw558-mdw558
-
Spain, L., Walls, G., Messiou, C., Turajlic, S., Gore, M. & Larkin, J. (2017). Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer immunology, immunotherapy, Vol.66(1), pp. 113-117
